Newland Pharmaceutical's Amlodipine Besylate API has recently received marketing approval from China's National Medical Products Administration (NMPA). This follows the approval of Levamlodipine Besylate and further expands Newland's portfolio of cardiovascular APIs. The approval strengthens our offering of calcium channel blocker (CCB) antihypertensive APIs and provides formulation manufacturers with another reliable and cost-effective supply option.

List of Approved API Products

With continuous R&D investment and efficient registration & submission work, our company has established an API portfolio covering multiple therapeutic areas including anti-infectives, cardiovascular & cerebrovascular drugs, anesthetics & analgesics, gastrointestinal medicines, anti-allergy agents and iron supplements. The key products and their applications are listed below:

About Amlodipine Besylate

Amlodipine Besylate is a long-acting calcium channel blocker (CCB) used to lower blood pressure and improve blood flow by relaxing blood vessels. It is indicated for the treatment of hypertension and coronary artery disease. It may also be used for chronic stable angina and vasospastic angina, either alone or in combination with other medications.

Pipeline Updates

Ruxolitinib Phosphate, Ilaprazole, and other products are progressing as planned. We will continue to expand our portfolio of specialty APIs and develop new products to create greater value for our customers.

Contact Us

For samples, quotations, or technical information, please contact us:

Tel: +86 138 1600 0664
Email: dma@newlandpharma.com

We look forward to exploring new opportunities with you.